Opinion
Video
The Role of Prescription Digital Therapeutics
Panelists discuss the limitations of traditional antipsychotics and the growing role of prescription digital therapeutics (PDTs) as complementary tools that align with younger patients’ digital habits, enhance engagement between visits, and enable real-time data tracking to improve proactive, personalized schizophrenia care.
The conversation turns to the limitations of traditional antipsychotic medications, particularly older agents that act primarily through D2 receptor antagonism. These treatments, although effective at reducing positive symptoms, often exacerbate negative and cognitive symptoms. Newer atypical antipsychotics and agents with novel mechanisms, such as those targeting muscarinic receptors, have expanded the treatment landscape. In addition, long-acting injectables offer valuable adherence solutions. However, medication alone does not address all aspects of schizophrenia, and participants highlight a growing interest in complementary approaches, such as PDTs.
PDTs, which use software-based interventions to deliver evidence-based therapies, are seen as a promising way to close treatment gaps. One clinician emphasizes how this modality aligns with the habits and preferences of younger patients, who represent the typical age of schizophrenia onset. Today’s youth, raised in a digital world, may feel more comfortable engaging with mobile platforms than traditional therapy. Apps can deliver psychoeducation, reinforce treatment goals, and provide interactive feedback, all in a format that fits seamlessly into their daily lives. Importantly, this allows for therapeutic engagement between clinic visits, especially for patients who cannot regularly attend in-person appointments.
Another key advantage the participants discuss is data tracking. Just as fitness devices can monitor sleep, activity, or mood-related behaviors, PDTs could collect real-time behavioral data to inform treatment. This information could alert providers to early signs of relapse or reduced functioning, enabling more proactive care. Participants agree that digital tools, while not a replacement for face-to-face care, offer a unique opportunity to bridge gaps, particularly in under-resourced or high-demand settings. As these technologies evolve, integrating them thoughtfully alongside pharmacologic and psychotherapeutic interventions may help create a more comprehensive and responsive treatment model for schizophrenia.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.
